EPIRUS Biopharmaceuticals to Release Third Quarter 2015 Financial Results and Provide Business Update
29 Outubro 2015 - 9:00AM
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical
company focused on the global development and commercialization of
biosimilar monoclonal antibodies (mAbs), today announced it will
release its third quarter 2015 financial results on Thursday,
November 12, 2015. In conjunction with the release, the
Company has scheduled a conference call and webcast on Thursday,
November 12, 2015 at 8:00 a.m. ET to discuss the financial results
and provide a business update.
Conference Call
InformationWhen: Thursday, November 12, 2015, 8:00 a.m.
ETDial-in: 1-855-638-3957 (United States) or 1-224-633-1318
(International)Conference ID: 67401555 Webcast:
http://ir.epirusbiopharma.com/events.cfmPlease join the conference
call at least 10 minutes early to register. The webcast will be
archived on EPIRUS' website for a period of three months.
About EPIRUS
BiopharmaceuticalsEPIRUS Biopharmaceuticals (Nasdaq:EPRS)
is a biopharmaceutical company focused on the global development
and commercialization of biosimilar monoclonal antibodies (mAbs).
EPIRUS’ goal is to improve global patient access to important,
cost-effective medicines. EPIRUS' current pipeline of
biosimilar product candidates includes: BOW015 (infliximab,
reference biologic Remicade®); BOW050 (adalimumab, reference
biologic Humira®); BOW070 (tocilizumab, reference biologic
Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090
(ustekinumab, reference biologic STELARA®); and BOW100 (golimumab,
reference biologic SIMPONI®)[i]. The reference products for these
candidates together generated approximately $29.2 billion in global
sales for 2014, according to EvaluatePharma®. EPIRUS has
established multiple partnerships to support its regulatory and
commercialization efforts in global markets. For more information
visit EPIRUS’ website at www.epirusbiopharma.com.
Contact Information:For
investor inquiries:Tom Shea, EPIRUS
Biopharmaceuticals+1-617-600-3471tshea@epirusbiopharma.com
For media inquiries:Mike Devine,
FleishmanHillard +1-212-453-2324 michael.devine@fleishman.com
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre EPIRUS Biopharmaceuticals Inc (CE) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de